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Introduction
There is a global epidemic of chronic kidney disease (CKD), with 
approximately one in ten adults affected.1 A systematic review of 
the CKD burden in sub-Saharan Africa by Stanifer et al. estimated 
the prevalence at 13.9%.2 Like most other countries, South 
Africa is also experiencing an increasing disease burden. Two 
studies from Cape Town have provided data on the population 
prevalence of CKD. Matsha et al.3 reported a prevalence of 
17.3% in a geographical cohort, while Adeniyi et al.4 reported a 
prevalence of 6.4% in a cohort of teachers. In their review on the 
burden of non-communicable diseases (NCDs) in South Africa, 
Mayosi et al.5 reported a 67% increase in deaths from kidney 
disease from 1999 to 2006.
Definition, diagnosis and staging of CKD
CKD is defined as abnormalities of kidney structure or function, 
present for three or more months, with implications for health 
and is classified based on the cause, glomerular filtration rate 
(GFR) category, and degree of albuminuria (Figure 1).6 Kidney 
damage may be detected by the presence of abnormalities of 
blood (e.g. high creatinine concentrations indicating low GFR) 
or urine (e.g. proteinuria or albuminuria), or by the presence of 
abnormalities on renal imaging (e.g. polycystic kidneys).
The accurate estimation of GFR is critically important in the 
diagnosis and staging of CKD. In routine clinical practice, 
GFR is usually estimated from measurements of creatinine 
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An epidemic of chronic kidney disease (CKD) is being experienced in South Africa. This is driven by a heavy burden of infections, 
non-communicable diseases, pregnancy-related diseases and injuries. The serious long-term complications of CKD include 
end-stage renal disease, heart disease and stroke. Competing priorities such as the high burden of HIV, tuberculosis and other 
infections, unemployment and poverty result in serious constraints to providing comprehensive renal care, especially in the public 
healthcare sector. The prevention and early detection of CKD by primary care practitioners is therefore of utmost importance. 
Annual screening is recommended for patients at high risk of developing CKD. This involves checking blood pressure, urine 
dipstick testing for albuminuria or proteinuria and estimating the glomerular filtration rate from serum creatinine concentrations. 
In patients with established CKD, renoprotective measures are indicated to arrest or slow down the loss of renal function. These 
patients are at high risk of cardiovascular disease and close attention should be paid to optimally managing their risk factors.
Figure 1. Diagnosis and classification of CKD by GFR and degree of albuminuria. Patients at low or moderate risk for disease progression (green/
yellow) should be followed up at least yearly, those at high risk (orange) twice-yearly, and those at very high risk (red) should be seen three or more 
times per year, as required. CKD—chronic kidney disease, GFR—glomerular filtration rate, KDIGO—Kidney Disease: Improving Global Outcomes. 
Reproduced from the KDIGO CKD guideline, with permission.7
Prognosis of CKD by GFR 
and albuminuria categories: 
KDIGO 2012
Persistent albuminuria categories  
Description and range
A1 A2 A3











G1 Normal or high >90
G2 Mildly decreased 60-89
G3a Mildly to moderately decreased 45-59
G3b Moderately to severely decreased 30-44
G4 Severely decreased 15-29
G5 Kidney failure <15
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concentrations in blood, using various prediction equations. 
The Modification of Diet in Renal Disease (MDRD) study and 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equations are the most commonly used formulae in adults. 
Current international guidelines recommend using the CKD-EPI 
equation unless another equation has superior accuracy in a 
specific population.6 
Tests to assess proteinuria may be more readily available and 
less expensive than those for albuminuria, and are an acceptable 
alternative (Table I). 
Screening for CKD
Individuals at increased risk for CKD should be screened annually.8 




• Cardiovascular, cerebrovascular or peripheral vascular disease
• Obesity
• Autoimmune diseases
• Prior acute kidney injury
• Prior pre-eclampsia, eclampsia or HELLP syndrome
• Age > 60 years
• Family history of kidney disease
Screening should involve blood pressure measurement, urine 
dipstick testing and estimation of GFR. If proteinuria is found 
on dipstick testing then it should be quantified by measuring 
the protein/creatinine ratio or albumin/creatinine ratio on a 
random urine sample. A 24-hour urine sample is not required. 
The preferred method of estimating GFR is the CKD-EPI equation.
Once a diagnosis of CKD is made, renal function should be 
monitored more frequently, especially in patients with GFR 
< 60 ml/min/1.73 m2, rapid GFR decline or risk factors for rapid 
GFR decline such as the use of nonsteroidal anti-inflammatory 
drugs or other potentially nephrotoxic medication and 
radiocontrast media.
Consequences of CKD
The obvious concern in a patient with CKD is progressive loss 
of renal function and the development of end-stage renal 
disease (ESRD) with the need for life-saving chronic dialysis 
or kidney transplantation. However, even those patients who 
do not progress to ESRD have an increased risk of death from 
cardiovascular and cerebrovascular disease.9 In fact, a patient with 
early stage CKD is far more likely to succumb to cardiovascular 
disease than to progress to ESRD. The presence of CKD is now 
recognised as an independent risk factor for cardiovascular 
disease.10,11 Cardiovascular mortality is 10 to 30 times higher 
than in the general population, after adjusting for factors such 
as sex, ethnicity and the presence of diabetes. The large burden 
of cardiovascular disease is attributed to the frequent presence 
of traditional factors, such as hypertension and dyslipidaemia, 
combined with the presence of non-traditional factors such as 
anaemia, chronic fluid overload, hyperphosphataemia, soft tissue 
and vascular calcification, chronic inflammation, malnutrition 
and hyperhomocysteinaemia. Patients with CKD are therefore a 
high-risk group and require optimal control of risk factors, such 
as aiming for lower blood pressure targets and treatment with 
specific agents.11
Drivers and common causes of CKD 
Increases in NCDs, pregnancy-related disorders, injuries and the 
high burden of infectious diseases all contribute to the epidemic 
of CKD being experienced in South Africa. CKD is a frequent 
complication of NCDs like diabetes mellitus and hypertension 
and may also follow on from acute kidney injury which has 
developed in the setting of infectious disease, complicated 
pregnancies, or injuries related to violence or road traffic 
accidents. 
In many cases of CKD, a specific diagnosis is never established 
because patients often present late, with poor renal function 
and shrunken kidneys, precluding a diagnostic kidney biopsy. 
In South African patients on renal replacement therapy (RRT), 
the most common reported renal diagnoses are hypertensive 
renal disease (34.7%), ESRD where the cause is unknown (32.4%), 
diabetic nephropathy (15.2%) and glomerular disease (9.9%).12 
In renal biopsy series, however, the most common diagnosis 
by far is glomerular disease.13 This reflects the indications for 
performing renal biopsies. For example, diabetic patients with a 
typical clinical picture of diabetic nephropathy are usually not 
biopsied.
Diabetic nephropathy
Worldwide, the most common cause of ESRD is diabetic 
nephropathy. It remains a clinical diagnosis (Table II) and only 
patients with atypical features should be referred for a kidney 
biopsy. Many of these patients will have a renal pathology other 
Table I. The relationship between the categories for albuminuria and proteinuria. Adapted from Eknoyan et al.6
Normal or mildly increased (A1) Moderately increased (A2) Severely increased (A3) Nephrotic range
Albumin excretion mg/24h < 30 30–300 > 300 > 2200
ACR mg/mmol < 3 3–30 > 30 > 220
ACR mg/g < 30 30–300 > 300 > 2200
Protein excretion g/24h < 0.150 0.150–0.500 > 0.500 > 3.50
PCR g/mmol < 0.015 0.015–0.050 > 0.050 > 0.35
PCR g/g < 0.150 0.150–0.500 > 0.500 > 3.50
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than diabetic nephropathy or will have diabetic nephropathy 
together with another renal disease.14 During the early stages 
of diabetic nephropathy, moderate albuminuria (previously 
referred to as microalbuminuria) may be found. This is defined 
as albuminuria of 30–300 mg/24 h, or 30–300 mg/g creatinine, 
in at least two out of three spot urine samples.15 The presence 
of moderate albuminuria increases the risk of progression 
to overt diabetic nephropathy by approximately 40%16 and 
confers increased risk for a cardiovascular event such as stroke 
or myocardial infarction.17 Optimisation of cardiovascular risk 
factors is particularly important in this group.
Table II. Criteria for the diagnosis of overt diabetic nephropathy18,19
1. In type 1 diabetics, a history of diabetes mellitus of >10 years. 
In type 2 diabetics, nephropathy may be present at the time of 
diagnosis.
2. Hypertension is usually present.
3. Persistent albuminuria/proteinuria. This tends to increase over 
time, eventually reaching the nephrotic range.
4. Diabetic retinopathy, especially in type 1 diabetics.
5. Progressive and sustained reduction in GFR to < 60 ml/min/1.73 m2.
The South African Renal Registry has reported that nearly 40% of 
patients receiving RRT are diabetic, while diabetic nephropathy 
is the primary renal diagnosis in 15.2%.12 Two studies have 
provided useful data on the long-term outcomes in South African 
patients with diabetes. Keeton et al.20 found that renal failure was 
a major cause of death in patients with type 2 diabetes. By the 
end of their 12-year study, 80% of the patients had died and of 
these deaths, 29% were due to ESRD. Gill et al.21 followed up type 
1 diabetic patients for 20 years and reported a crude mortality 
rate of 43%, with 43% of these deaths due to renal failure.
Glomerulonephritis
Renal biopsy series indicate that mesangiocapillary 
glomerulonephritis (GN) is the most common primary 
glomerular disease encountered in the Cape Town area,13,22 
while focal segmental glomerulosclerosis is the most common 
in the north of the country.23,24 Lupus nephritis is the most 
common secondary glomerular disease throughout the country. 
HIVAN, the most commonly identified renal pathology in HIV-
positive patients, and diabetic nephropathy are the other 
common secondary forms of glomerular disease. Postinfectious 
glomerulonephritis, which is now rare in high-income countries, 
remains a significant problem in South Africa.
HIV infection
HIV-infected patients may develop CKD due to HIV-associated 
nephropathy (HIVAN), HIV-related immune complex disease, 
or following acute kidney injury related to infections or drug 
toxicity. The first report of HIVAN from South Africa was published 
by Bates et al. in 1994.25 Despite having advanced kidney disease 
and nephrotic-range proteinuria, patients with HIVAN frequently 
do not have hypertension or significant peripheral oedema. 
The condition occurs especially in the absence of antiretroviral 
therapy and in patients with markedly reduced CD4 counts 
and elevated viral loads.26 Individuals of African descent have 
a genetic susceptibility that is related to polymorphisms in the 
apolipoprotein L1 (APOL1) gene.27 Two South African studies28,29 
have demonstrated the benefit of ART on renal outcomes in 
both HIVAN and HIV-related immune complex disease. 
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Hypertensive renal disease
In our registry data, hypertension has been reported as the 
aetiology of ESRD in 34.7% of patients.12 However, in the largest 
South African renal biopsy series,13 hypertensive renal disease 
was diagnosed in only 2.7% of cases despite approximately 
half of the patients being hypertensive. Many patients labelled 
as having “hypertensive renal disease” probably have primary 
glomerular disease and secondarily elevated blood pressure.30 
Hypertension should be recorded as the renal diagnosis only 
when the following criteria are met: hypertension known 
to precede renal dysfunction, left ventricular hypertrophy, 
proteinuria < 2 g/day, and no evidence of other renal diseases.31,32
CKD in children
Infants commonly suffer from congenital abnormalities of 
the kidney and urinary tract (CAKUT).33 In older children, 
post-infectious glomerulonephritis is a common cause of 
acute nephritis. This usually resolves completely but a small 
proportion of children go on to develop CKD. Minimal change 
disease remains the predominant cause of childhood nephrotic 
syndrome. This mostly responds to steroids during early 
childhood and goes into remission after adolescence. HIV-
associated renal disease is now rare since the implementation 
of the Maternal-to-Child-Transmission Prevention programmes 
and the availability of ART34 and hepatitis B-related nephrotic 
syndrome has virtually disappeared since the introduction of 
routine hepatitis B immunisation in 1995.35,36
Renal replacement therapy 
In December 2016, the number of patients who were treated 
with chronic dialysis or kidney transplantation stood at 10 
257, a prevalence of 183 per million population (pmp).12 
The treatment modality was haemodialysis in 73.4%, 
peritoneal dialysis in 12.7% and transplantation in 13.9%. 
This is very different from the situation two decades ago 
when RRT was mainly delivered by government-funded 
public sector facilities and more than half of all patients 
had functioning kidney transplants.37 
There has been a steady increase in the number of patients 
accessing haemodialysis in the private healthcare sector, 
where the treatment of ESRD is a “prescribed minimum 
benefit” for patients who are beneficiaries of medical aid 
schemes. The prevalence of treated ESRD in the private 
sector is on par with that of many high-income countries 
(798 pmp), whereas, in the public sector, the prevalence 
(68 pmp) has fallen below the level reported for 1994. 
This rate of treatment is well below that of countries with 
similar or lesser GNIPC. There are also large disparities 
in access to RRT between ethnic groups and between 
different provinces, with Blacks being the most under-
served group and with two provinces (Limpopo and 
Mpumalanga) having no public sector dialysis centres at 
all.12 
Because of resource constraints, national guidelines 
mandate that only patients who are transplantable can 
be accepted onto public sector dialysis programmes. In the 
Western Cape, guidelines for selecting patients for RRT have 
been developed after extensive consultation with stakeholders, 
including patient representatives and ethics experts.38
The survival of South African patients on RRT compares well with 
survival rates reported from better-resourced countries.39 One-
year survival in incident patients is 90.4%, and 90.1% in prevalent 
patients. There were no differences between public and private 
healthcare sectors.  
Renal transplants are performed in six public sector and nine 
private sector centres.12 Moosa40 recently reviewed 25 years of 
transplantation in South Africa. During the period 1991–2015, 
7 191 kidney transplants were performed, the majority (58.3%) 
derived from deceased donors. Hospitals in Cape Town and 
Johannesburg performed over 75% of these transplants. The 
trend has been towards a decline in the annual number of 
kidney transplants performed (Figure 3). Poor consent rates for 
kidney donation have been linked to education, religious beliefs, 
cultural traditions and a lack of transplant coordinators speaking 
the different local languages.40,41
Management of CKD and referral to a nephrologist
Patients with renal disease should be referred to a nephrologist 
when there is doubt about the diagnosis, such as in the case 
of unexplained acute kidney injury, nephrotic syndrome or 
nephritis as part of a systemic disease. These patients warrant a 
renal biopsy and may require specific therapy. Typical cases of 
post-infectious nephritis or diabetic nephropathy do not usually 
require a biopsy.
Figure 3. Numbers of deceased and living donor kidney transplants in South 
Africa, 2000–2015.40
Deceased donor (n = 2 690)
Living donor (n = 1 855)
Linear (deceased donor (n = 2 690))
Linear (living donor (n = 1 855))
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The management of patients with established CKD revolves 
around the effective control of the underlying disease (e.g. 
immunosuppression in lupus nephritis), and strategies to 
arrest or slow the progressive loss of renal function through 
renoprotective measures. These include the following:
• Avoidance of nephrotoxic agents
• Prompt treatment of urinary tract infections
• Stopping smoking
• Low salt diet
• Good blood pressure control
• The use of angiotensin converting enzyme inhibitors or 
angiotensin receptor blockers, especially in patients with 
proteinuria
• Good blood glucose control in diabetics (as GFR declines, 
patients will be prone to hypoglycaemia and medications may 
have to be reduced or stopped)
The two most important measures to halt or slow down the 
progression of CKD to ESRD, regardless of the cause, are 
controlling blood pressure and reducing proteinuria. The most 
important anti-hypertensive drug class that addresses both 
of these factors is the renin-angiotensin-aldosterone system 
inhibitors (RAASi), including the angiotensin-converting 
enzyme inhibitors and the angiotensin receptor blockers. 
Other than systemic hypertension, patients with CKD also have 
intraglomerular hypertension. RAASi reduces intraglomerular 
pressure by dilating the glomerular efferent arteriole, thus 
decreasing both glomerular filtration pressure and proteinuria. 
The net result is increased nephron longevity. However, these 
agents may impair renal potassium excretion and patients should 
be monitored for hyperkalaemia since the CKD population is 
already at risk of developing this complication. 
In addition, patients with CKD have so-called salt-sensitive or 
volume-dependent hypertension and therefore a low-salt diet 
and diuretic use are important in improving blood pressure 
control in this population. A salt-restricted diet of less than 
6 g/day (a level teaspoon) is recommended.42 High salt intake 
negates the effects of RAASi and diuretics. Thiazide diuretics, 
such as hydrochlorothiazide, are effective when GFR is greater 
than 30 ml/min/1.73 m2. Once GFR falls below this level, it should 
be substituted with a loop diuretic such as furosemide.43 The 
international KDIGO guidelines recommend a blood pressure 
target of less than or equal to 130/80 mmHg for all patients with 
CKD and proteinuria greater than 150 mg/day, regardless of 
diabetic status.6    
If the CKD progresses despite these measures, patients should 
be referred for consideration of RRT, especially once the GFR 
approaches 30 ml/min/1.73 m2. Timeous referral allows for the 
different options for renal replacement to be discussed and for 
preparations such as the screening of potential kidney donors or 
the creation of an arteriovenous fistula for chronic haemodialysis.
Conclusions
Like many African countries, South Africa faces an epidemic 
of chronic kidney disease. There are many competing health 
priorities, resulting in serious resource constraints to providing 
comprehensive renal care, especially in the public healthcare 
sector. The prevention and early detection of CKD by primary 
care practitioners is therefore of utmost importance. In patients 
with established CKD, renoprotective measures may arrest or 
slow down the loss of renal function. These patients are at high 
risk of cardiovascular disease and close attention should be paid 
to optimally managing their risk factors.
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